Furthermore, in vitro and in vivo (mouse model) studies confirmed that AED T cells can recognize and clear CD19+ human tumour cells when co-administered with blinatumomab and yet, in the presence of cognate peptide antigen, remain unresponsive, thus lowering the risk of alloreactive responses (GvHD). The gene discussed is CD19; the disease is neoplasm.